Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Stemirna Planning Phase III Trial of COVID mRNA Vaccine in Brazil
“We will publish data for the Phase 1 trial (conducted in
Stemirna's COVID vaccine joins another mRNA vaccine under development in
China's other COVID vaccines (not mRNA) are based on a dead or weakened form of the virus, the traditional mechanism for vaccines. The mRNA vaccines, like the BioNTech and Moderna products, are surprisingly effective compared to older types of vaccines.
In addition, Stemirna believes its mRNA vaccine may be better than these other mRNA vaccines. Stemirna's LPP (lipopolyplex) nano-delivery platform is a core-shell structure, with polymer-mixed mRNA as the core and lipids as the shell. Moderna and Pfizer, on the other hand, use a lipid nanoparticle (LNP) technology to deliver a variety of nucleic acids in vivo and in vitro.
“Compared with traditional LNP platforms that most companies are adopting, the core-shell structured LPP particle is better at protecting mRNA, and is able to release mRNA gradually as the polymers are degraded,” said Shen Haifa, Stemirna's chief technology officer.
Stemirna CEO Li obtained his doctorate in cancer biology from MD Anderson Cancer Center of the
See our other articles on Stemirna.